Literature DB >> 12502811

A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.

Ali M Harandi1, Kristina Eriksson, Jan Holmgren.   

Abstract

Unmethylated CpG dinucleotides in bacterial DNA or synthetic oligodeoxynucleotides (ODNs) are known as potent activators of the immune system and inducers of several Th1-associated immunomodulatory cytokines. We therefore investigated whether such a CpG-containing ODN (CpG ODN) given mucosally in the female genital tract could enhance innate immunity and protect against genital herpes infection. Groups of C57BL/6 mice were treated intravaginally with either CpG ODN or a non-CpG ODN control in the absence of any antigen either 2 days before or 4 h after an intravaginal challenge with a normally lethal dose of herpes simplex virus type 2 (HSV-2). Mice treated with CpG ODN exhibited significantly decreased titers of HSV-2 in their vaginal fluids compared with non-CpG ODN-treated mice. Furthermore, CpG ODN pretreatment significantly protected against development of disease and death compared to non-CpG ODN pretreatment. Most strikingly, CpG ODN conferred protection against disease and death even when given after the viral challenge. The CpG ODN-induced protection was associated with a rapid production of gamma interferon (IFN-gamma), interleukin-12 (IL-12), IL-18, and RANTES in the genital tract mucosa following CpG ODN treatment. The observed protection appeared to be dependent on IFN-gamma, IL-12, IL-18, and T cells, as CpG ODN pretreatment did not confer any significant protection in mice deficient in IFN-gamma, IL-12, IL-18, or T cells. Further, a complete protective immunity to reinfection was elicited in CpG ODN-treated, HSV-2-challenged mice, suggesting a role for mucosally administered CpG ODN in inducing the development of an acquired immune response in addition to its potent stimulation of innate immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502811      PMCID: PMC140825          DOI: 10.1128/jvi.77.2.953-962.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

Authors:  A M Harandi; B Svennerholm; J Holmgren; K Eriksson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 2.  Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity.

Authors:  Hermann Wagner
Journal:  Curr Opin Microbiol       Date:  2002-02       Impact factor: 7.934

3.  Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1).

Authors:  M L Dustin; R Rothlein; A K Bhan; C A Dinarello; T A Springer
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

4.  Antigenic differences between isolates of herpesvirus type 2.

Authors:  P Seth; W E Rawls; R Duff; F Rapp; E Adam; J L Melnick
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

5.  Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.

Authors:  L Corey; A G Langenberg; R Ashley; R E Sekulovich; A E Izu; J M Douglas; H H Handsfield; T Warren; L Marr; S Tyring; R DiCarlo; A A Adimora; P Leone; C L Dekker; R L Burke; W P Leong; S E Straus
Journal:  JAMA       Date:  1999-07-28       Impact factor: 56.272

Review 6.  Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world.

Authors:  A J Nahmias; F K Lee; S Beckman-Nahmias
Journal:  Scand J Infect Dis Suppl       Date:  1990

7.  Specific effect of interferon on the herpes simplex virus type 1 transactivation event.

Authors:  P R De Stasio; M W Taylor
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 8.  Recent developments in herpesvirus therapy.

Authors:  L Naesens; E De Clercq
Journal:  Herpes       Date:  2001-03

9.  Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-gamma-dependent RANTES production following a vaginal viral challenge.

Authors:  A M Harandi; B Svennerholm; J Holmgren; K Eriksson
Journal:  Am J Reprod Immunol       Date:  2001-12       Impact factor: 3.886

10.  Evaluation of solubilized herpes simplex virus membrane antigen by enzyme-linked immunosorbent assay.

Authors:  S Jeansson; M Forsgren; B Svennerholm
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

View more
  46 in total

1.  Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.

Authors:  Hai-yan Du; Li-hou Dong; Bi-jun Zhao; Jie Fu; Qing-qing Wang; Fang Chen; Lun Ou; Na Li; Xiao Sun; Zhong-ming Tang; Hai-feng Song
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

2.  Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.

Authors:  Soumi Gupta; Ramesh Janani; Qian Bin; Paul Luciw; Catherine Greer; Silvia Perri; Harold Legg; John Donnelly; Susan Barnett; Derek O'Hagan; John M Polo; Michael Vajdy
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.

Authors:  Aziz Alami Chentoufi; Gargi Dasgupta; Anthony B Nesburn; Ilham Bettahi; Nicholas R Binder; Zareen S Choudhury; Winston D Chamberlain; Steven L Wechsler; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

4.  A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide.

Authors:  Hong Shen; Akiko Iwasaki
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

5.  RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2.

Authors:  Daniel J J Carr; Lisa Tomanek; Robert H Silverman; Iain L Campbell; Bryan R G Williams
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.

Authors:  Xian-Song Wang; Zhen Sheng; You-Bing Ruan; Yang Guang; Mu-Lan Yang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

8.  CpG DNA induces protective antiviral immune responses in Atlantic salmon (Salmo salar L.).

Authors:  Jorunn B Jørgensen; Lill-Heidi Johansen; Kari Steiro; Audny Johansen
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection.

Authors:  Rhonda D Cardin; Fernando J Bravo; Andrea P Sewell; James Cummins; Louis Flamand; Jean-Marc Juteau; David I Bernstein; Andrew Vaillant
Journal:  Virol J       Date:  2009-12-02       Impact factor: 4.099

10.  FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.

Authors:  William A Rose; Chris L McGowin; Richard B Pyles
Journal:  Virol J       Date:  2009-11-10       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.